睡眠期间的声学刺激预测了老年人的记忆性能和有益的粉样蛋白反应的长期增长
Marina Wunderlin1,2, Céline Jacqueline Zeller1,2, Samira Rafaela Senti1
1University Hospital of Old Age Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland.
Age and ageing
|January 1, 2024
概括
阶段锁定声学刺激 (PLAS) 改善了睡眠质量,并在老年人中显示出长期记忆的好处. 这种非侵入性技术可以通过清除粉样蛋白代谢物来帮助预防认知衰退.
科学领域:
- 神经科学是一个神经科学.
- 睡眠科学 睡眠科学
- 老年学是一门学科.
背景情况:
- 睡眠障碍和神经退行与有害循环有关.
- 改善睡眠可能是预防神经退行性疾病的策略.
- 阶段锁定声学刺激 (PLAS) 被探索为一种非侵入性睡眠增强方法.
研究的目的:
- 研究多夜PLAS对慢波睡眠 (SWS) 的影响.
- 评估PLAS对记忆表现和粉样蛋白水平的影响.
- 为了确定PLAS是否可以减轻睡眠不足和神经退行之间的循环.
主要方法:
- 在SWS期间使用PLAS进行了为期三天的假控制干预.
- 这项研究涉及32名健康的老年人 (平均年龄68.9岁).
- 参与者在干预前一晚接受了基线假PLAS.
主要成果:
- PLAS增加了与睡眠相关的光谱功率和缓慢波合螺旋.
- 干预后立即没有发现记忆或粉样β的显著群体差异.
- PLAS诱导的生理变化的程度与持续的记忆性能和粉样蛋白变化相关.
结论:
- 在老年人中,多个晚上的PLAS显示了长期记忆效益和改善代谢物清除的潜力.
- PLAS是开发长期战略以防止认知衰退的有希望的工具.
- 对长期PLAS协议的进一步研究是有必要的.
相关概念视频
Cognitive Development During Adulthood
114
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
114
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
127
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
127
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


